Skip to Main Content

Good morning, everyone, and how are you today? We are coping, thank you, despite the raging tumult underway beyond the walls of the Pharmalot campus. For those needing a moment of relief, allow us to pass along a quip from years past: When told the sky was falling, Chicken Little had but one reaction: Sell sky! And now, on with the show. Time for a cup of stimulation and a look at the to-do list. Hope your day goes well and you remain healthy.

In response to the novel coronavirus and drug shortages in general, two senators introduced a bill to funnel $100 million to increase U.S. production of medicines and active pharmaceutical ingredients, CNBC says. The legislation sponsored by Marsha Blackburn, R-Tenn., and Bob Menendez, D-N.J., would expand upon the Emerging Technology Program within the Food and Drug Administration to prioritize issues related to national security and critical drug shortages, as well as bring pharmaceutical manufacturing jobs to the U.S.


As they race to test an experimental coronavirus vaccine, researchers are not waiting to see how well it prevents infection in animals before trying it in people, breaking from the usual protocol, STAT explains. Normally, regulators require that a manufacturer show a product is safe before it goes into people, and while it is not enshrined in law, researchers almost always check that a new concoction is effective in lab animals before putting human volunteers at potential risk.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!